Market News & Trends
Sarepta Therapeutics Announces Positive & Robust Expression & Biomarker Data
Sarepta Therapeutics, Inc. recently announced positive results from three Limb-girdle muscular dystrophy (LGMD) Type 2E clinical trial participants who received MYO-101. MYO-101 is a novel…
SAMDI Tech Provides 1+ Million Compounds Through WuXi Partnership for Drug Candidate Screening
SAMDI Tech Inc., the industry’s leading provider of label-free drug discovery solutions, now has well over 1 million compounds in its small molecule screening collection,…
Foamix Announces Positive Results From Phase 3 Open-Label Safety Study Evaluating Topical Minocycline Foam
Foamix Pharmaceuticals Ltd. recently announced positive safety and efficacy data for its Phase 3 open-label safety study (FX2016-13), evaluating FMX103 in moderate-to-severe papulopustular rosacea for…
ABclonal Technology Partners With BenchSci to Boost Discoverability of its Novel Products
ABclonal Technology and BenchSci have recently entered into a partnership to provide scientists with high-class research tools for accelerating biomedical discoveries. Research scientists have always…
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study
Cellectar Biosciences, Inc. recently announced additional positive top-line results from its ongoing Phase 2 clinical study of CLR 131, the company’s lead product candidate. In…
Nuvec: A Breakthrough Technology for mRNA/pDNA Delivery for Vaccines & Cancer Treatments
N4 Pharma Plc, a specialist pharmaceutical company, is developing Nuvec – a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle…
Rockland Immunochemicals & Cellaria Sign Worldwide Distribution Agreement
Cellaria, LLC recently announced a new distribution partnership with Rockland Immunochemicals, Inc. (Rockland) that gives Rockland the rights to market and sell Cellaria’s high-quality next generation in-vitro disease models and cell culture media worldwide.
AKCEA-APO(a)-LRx Advances as Novartis Exercises Option to License
Akcea Therapeutics, Inc. recently announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD).
U.S. FDA Grants Breakthrough Therapy Designation to Amicus Therapeutics
Amicus Therapeutics recently announced that the US FDA has granted to Amicus a Breakthrough Therapy Designation (BTD) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA).
BrainStorm Announces First Contracted US Clinical Site for Phase 2 Progressive MS Study
BrainStorm Cell Therapeutics Inc. recently announced Cleveland Clinic as the first US clinical site contracted for a planned Phase 2 open-label, multicenter study of repeated…
Mogrify Raises $3.7 Million to Accelerate Mission to Transform Cell Therapy Via Direct Cellular Conversion
Cell Mogrify Ltd (Mogrify) recently announced a second close on its seed funding, bringing the total raised to $3.7 million, and the appointment of Darrin…
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial
ARCA biopharma, Inc. recently announced it has reached agreement with the US FDA regarding a Special Protocol Assessment (SPA) on the design of a pivotal…
Saama Partners With The Leukemia & Lymphoma Society & Unveils New Capabilities for Award-Winning Life Science Analytics Cloud
Saama Technologies, Inc. recently announced a new partnership with The Leukemia & Lymphoma Society (LLS), the world’s largest nonprofit dedicated to fighting blood cancers, to…
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial
ADC Therapeutics recently announced the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of…
CytoDyn Files for Orphan Drug Designation for Triple-Negative Breast Cancer
CytoDyn Inc. recently announced it was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model…
Sapreme Technologies to Develop an Oligonucleotide Delivery Platform
Sapreme Technologies has been awarded a $7.71 million grant together with a multidisciplinary consortium including 11 other academic and industrial parties.
PPD & HLT to Create Data Science-Driven Clinical Research Solutions
Pharmaceutical Product Development, LLC and Happy Life Tech of China have signed an exclusive agreement to develop a distinctive service offering for the China drug development market delivering data science-driven clinical trials and real-world evidence of drug products’ effectiveness, safety, and value.
Moleculin Announces Out-Licensing Deal to Accelerate Preclinical & Clinical Development
Moleculin Biotech, Inc. recently announced it has entered into a sub-license agreement with WPD Pharmaceuticals (WPD), located in Poland.
Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived From Endothelial Cells
Avalon GloboCare Corp. recently announced its ongoing co-development program with Weill Cornell Medicine, led by Yen-Michael Hsu, MD, PhD, Director of cGMP Cellular Therapy Facility…
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Eton Pharmaceuticals, Inc. recently announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a Swiss-based pharmaceutical company, to obtain…
